D
Daniel C. Chung
Researcher at Harvard University
Publications - 307
Citations - 27050
Daniel C. Chung is an academic researcher from Harvard University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 69, co-authored 290 publications receiving 24211 citations. Previous affiliations of Daniel C. Chung include University of Pennsylvania & Google.
Papers
More filters
Journal ArticleDOI
The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis.
TL;DR: Insights into the molecular basis of the relatively rare inherited syndromes familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer have had profound implications for tumorigenesis in the more widespread sporadic forms of colon cancer.
Journal ArticleDOI
Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer
Pardeep Kaurah,Andrée MacMillan,Niki Boyd,Janine Senz,Alessandro De Luca,Nicki Chun,Gianpaolo Suriano,Sonya Zaor,Lori Van Manen,Cathy Gilpin,Sarah M. Nikkel,Mary Connolly-Wilson,Scott M. Weissman,Wendy S. Rubinstein,Courtney Sebold,Robert M. Greenstein,Jennifer Stroop,Dwight Yim,Benoit Panzini,Wendy McKinnon,Marc S. Greenblatt,Debrah Wirtzfeld,Daniel Fontaine,Daniel G. Coit,Sam S. Yoon,Daniel C. Chung,Gregory Y. Lauwers,Antonio Pizzuti,Carlos A. Vaccaro,Maria Ana Redal,Carla Oliveira,Marc Tischkowitz,Sylviane Olschwang,Steven Gallinger,Henry T. Lynch,Jane Green,James M. Ford,Paul D.P. Pharoah,Bridget A. Fernandez,Bridget A. Fernandez,David G. Huntsman +40 more
TL;DR: Recurrent CDH1 mutations in families with hereditary diffuse gastric cancer are due to both independent mutational events and common ancestry, and the presence of a founder mutation from Newfoundland is strongly supported.
Journal ArticleDOI
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett,Jean Bennett,Manzar Ashtari,Jennifer Wellman,Kathleen A. Marshall,Laura Cyckowski,Daniel C. Chung,Daniel C. Chung,Sarah McCague,Eric A. Pierce,Eric A. Pierce,Yifeng Chen,Jeannette L. Bennicelli,Xiaosong Zhu,Gui-Shuang Ying,Junwei Sun,J. Fraser Wright,Alberto Auricchio,Francesca Simonelli,Kenneth S. Shindler,Federico Mingozzi,Katherine A. High,Katherine A. High,Albert M. Maguire,Albert M. Maguire +24 more
TL;DR: The researchers report that the lack of immune response and the robust safety profile in this readministration gene therapy study may be due in part to the immune-privileged nature of the eye, and the low dose and very pure preparation of the AAV vector.
Journal Article
Founder and Recurrent CDH1 mutations in families with Hereditary diffuse gastric Cancer. Editorial
Pardeep Kaurah,Andrée MacMillan,Niki Boyd,Janine Senz,Alessandro De Luca,Nicki Chun,Gianpaolo Suriano,Sonya Zaor,Lori Van Manen,Cathy Gilpin,Sarah M. Nikkel,Mary Connolly-Wilson,Scott M. Weissman,Wendy S. Rubinstein,Courtney Sebold,Robert M. Greenstein,Jennifer Stroop,Dwight Yim,Benoit Panzini,Wendy Mekinnon,Marc S. Greenblatt,Debrah Wirtzfeld,Daniel Fontaine,Daniel G. Coit,Sam S. Yoon,Daniel C. Chung,Gregory Y. Lauwers,Antonio Pizzuti,Carlos A. Vaccaro,Maria Ana Redal,Carla Oliveira,Marc Tischkowitz,Sylviane Olschwang,Steven Gallinger,Henry T. Lynch,Jane Green,James M. Ford,Paul D.P. Pharoah,Bridget A. Fernandez,David G. Huntsman,Kirsten N. Kangelaris,Stephen B. Gruber +41 more
TL;DR: In this paper, the authors performed a haplotype analysis to determine whether recurring germline CDH1 mutations occurred due to independent mutational events or common ancestry in 28 families diagnosed clinically with hereditary diffuse gastric cancer.
Journal ArticleDOI
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Jean Bennett,Jean Bennett,Jennifer Wellman,Kathleen A. Marshall,Sarah McCague,Manzar Ashtari,Manzar Ashtari,Julie DiStefano-Pappas,Okan U. Elci,Daniel C. Chung,Junwei Sun,Junwei Sun,J. Fraser Wright,Dominique Cross,Puya Aravand,Laura Cyckowski,Jeannette L. Bennicelli,Federico Mingozzi,Alberto Auricchio,Eric A. Pierce,Jason Ruggiero,Bart P. Leroy,Bart P. Leroy,Francesca Simonelli,Katherine A. High,Katherine A. High,Albert M. Maguire +26 more
TL;DR: To the knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye and the results highlight the use of several outcome measures and help to delineate the variables that contribute to maximal benefit from gene augmentation therapy in this disease.